Key points are not available for this paper at this time.
The use of immune checkpoint inhibitors (ICIs) - including ipilimumab, nivolumab, and atezolizumab has demonstrated remarkable clinical efficacy in cancer therapy. However, due to the activation of the immune system, ICIs can also precipitate immune-related adverse events (irAEs) across multiple organ systems. Among these toxicities, checkpoint inhibitor-related pneumonitis (CIP) is uncommon but carries substantial mortality and poses notable diagnostic and therapeutic challenges. In this review, we summarize the current advances regarding the risk factors and mechanisms of CIP and provide an overview of its incidence and mortality, imaging characteristics, diagnostic approaches, and treatment strategies.
Chen et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: